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Background & Aims 
Liver fibrogenesis is sustained by myofibroblast-like cells originating from hepatic stellate 
cells (HSC/MFs), portal fibroblasts or bone marrow-derived cells, including mesenchymal 
stem cells (MSCs). Herein, we investigated the mechanistic role of intracellular generation 
of reactive oxygen species (ROS) and redox-sensitive signal transduction pathways in 
mediating chemotaxis, a critical profibrogenic response for human HSC/MFs and for MSC 
potentially engrafting chronically injured liver. 
Methods 
Intracellular generation of ROS and signal transduction pathways were evaluated by 
integrating morphological and molecular biology techniques. Chemokinesis and 
chemotaxis were evaluated by wound healing assay and modified Boyden’s chamber 
assay, respectively. Additional in vivo evidence was obtained in human specimens from 
HCV-related cirrhosis. 
Results 
Human MSCs and HSC/MFs migrate in response to a panel of polypeptide 
chemoattractants and extracellularly generated superoxide anion. All polypeptides induced 
a NADPH-oxidase-dependent intracellular rise in ROS, resulting in activation of ERK1/2 
and JNK1/2. Moreover, menadione or 2,3-dimethoxy-1,4-naphthoquinone, which generate 
intracellular superoxide anion or hydrogen peroxide, respectively, induced ERK1/2 and 
JNK1/2 activation and migration. JNK1 activation was predominant for migration as shown 
by specific silencing. Finally, activation of ERK1/2 and JNK1/2 was found in extracts 
obtained from HSC/MFs during the course of an oxidative stress-mediated model of liver 
injury and phosphorylated JNK1/2 isoforms were detected in α-smooth muscle actin-
positive myofibroblasts lining fibrotic septa in human cirrhotic livers. 
Conclusions 
Intracellular generation of ROS, through activation of specific signaling pathways, is a 
critical event for directional migration of HSC/MFs and MSCs. 
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HSC/MFs, hepatic stellate cells; MSCs, mesenchymal stem cells; ROS, reactive oxygen 
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Introduction 
Fibrotic progression of chronic liver diseases (CLDs) is sustained by hepatic populations of 
myofibroblast-like cells (MFs) that originate mainly from activation of hepatic stellate cells 
(HSC) and portal (myo)fibroblasts [1], [2], [3], [4] and [5] or, to a lesser extent, through 
epithelial to mesenchymal transition (EMT) of hepatocytes and/or cholangiocytes [3], or 
circulating and bone marrow-derived mesenchymal stem cells (MSCs) or 
fibrocytes [4] and [5] engrafting chronically injured liver. Most of our knowledge derives 
from studies on fully activated, MF-like HSC (HSC/MFs) and their phenotypic responses 
(proliferation, increased synthesis of ECM, and pro-inflammatory mediators, migration, 
contractility) that are initiated and/or sustained by growth factors, chemokines, 
adipokines [1], [2], [3], [4] and [5], reactive oxygen species (ROS), and other mediators [6]. 
Whatever their origin be, MFs ability to migrate towards the site of injury and to align with 
nascent and established fibrotic septa represents a relevant pro-fibrogenic feature which, 
in turn, may be critical in recruiting circulating MSCs and driving their migration once 
differentiated into a MF-like phenotype. Induction of HSC/MFs chemotaxis is stimulated by 
polypeptides overexpressed during CLDs, including platelet-derived growth factor (PDGF), 
monocyte chemoattractant protein-1 (MCP-1 or CCL2) [7], angiotensin II (AT-II) [8], 
vascular-endothelial growth factor (VEGF), angiopoietin-1 [9], and ROS like superoxide 
anion [10] and [11]. PDGF, the best characterized and most potent chemoattractant for 
HSC/MFs, is also active on human MSC in their fibroblast-like and α-SMA-positive 
phenotype [12]. Moreover, chemoattractants operate by activating Ras/ERK signaling, with 
only PDGF being able to activate PI-3 K/c-Akt 
signaling [1], [2],[6], [7], [8], [9], [10], [11] and [12]. 
In this study, we show that all effective stimuli for profibrogenic human HSC/MFs and bone 
marrow-derived fibroblast-like MSCs require, as a common critical step, intracellular 
generation of ROS in order to trigger chemotaxis through a mechanism that involves 
redox-sensitive activation of ERK1/2 and JNK1/2. 
Materials and methods 
Materials 
Human recombinant growth factors and cytokines were from PeproTech Inc. (Rocky Hill, 
NJ). Monoclonal and polyclonal antibodies against phosphorylated and unphosphorylated 
ERK1/2 or JNK1/2 were from Santa Cruz Biotechnology (Santa Cruz, CA) or Cell 
Signaling Technology (Beverly, MA), respectively. SP600125 and PD98095 were from 
Calbiochem (La Jolla, California, USA). Male adult Wistar rats were from Harlan-Nossan 
(Correnzana, Italy). The enhanced chemiluminescence reagents and nitrocellulose 
membranes (Hybond-C extra) were from Amersham Pharmacia Biotech (Milano, Italy). All 
other reagents were from Sigma Aldrich Spa (Milan, Italy). 
Isolation and culture of hepatic stellate cells and mesenchymal stem 
cells 
Human HSC were isolated and characterized [13] from surgical wedge sections of at least 
three different human livers not suitable for transplantation after obtaining the approval of 
the Human Research Review Committee (University of Florence). HSC were cultured as 
previously described [9] and [11], used between passages 4 and 7 (fully activated 
HSC/MFs), plated to obtain the desired sub-confluence level, and then left for 24 h in 
serum-free Iscove’s medium to have cells at the lowest level of spontaneous proliferation. 
Procedures for isolation of rat HSCs have also been extensively described[14]. 
Bone marrow cells were obtained from human donors after informed consent. Aliquots of 
2–3 ml of whole bone marrow were seeded in MSC-medium MEM (Lonza, Versviers, 
Belgium) at 10% of fetal bovine serum and cultured for 5 days. Adherent cells, when at 
confluence, were detached by Trypsin/EDTA, seeded at 1000/cm2, expanded, and used 
for “in vitro” experiments from passage 3 to passage 7, when displaying a fibroblast-like 
and α-SMA positive phenotype [12]. Immunophenotypic analysis of hMSCs and their 
differentiative potential have been described elsewhere [12] and [15]. MSCs used were 
always more than 90% positive (cytofluorimetric analysis) for CD90, CD73, CD105, and 
CD29 but negative for CD34, CD45, and CD14. 
Animal experiments 
Male adult Wistar rats, initial weight 200–220 g, receiving human care and with 
experimental protocols performed according to national and local guidelines, were fed a 
standard pelleted diet and water ad libitum. Acute liver injury was induced by single oral 
treatment with carbon tetrachloride (CCl4) and animals were sacrificed from 24 to 96 h, as 
previously described [16]. 
Cell migration and chemotaxis 
Non-oriented migration (chemokinesis) and chemotaxis of human HSC/MFs and human 
MSCs were evaluated by performing the wound healing assay (20 h of incubation) or the 
modified Boyden’s chamber assay (6 h of incubation), as described [9], [11] and [16]. 
Molecular biology procedures 
Total cell extracts were subjected to SDS–PAGE on 10% or 7.5% acrylamide gels. The 
blots were incubated with desired primary antibodies and then with peroxidase-conjugated 
anti-mouse or anti-rabbit immunoglobulins in Tris-buffered saline–Tween containing 2% 
(w/v) non-fat dry milk [9] and [16] and developed with the enhanced chemiluminescence 
reagents according to manufacturer’s instructions. 
Target siRNA sequences for down-regulation of human JNK isoforms are: 
(1) 
(5′-GAAAGAATGTCCTACCTTCT-3′), found in both JNK1 mRNA (nucleotide 393–
412) and JNK2 mRNA (nucleotide 425–444) [17]. 
(2) 
(5′-GTGGAAAGAATTGATATATAA-3′) found in JNK1 mRNA. 
(3) 
(5′-AAGAGAGCTTATCGTGAACTT-3′) found in JNK2 mRNA. 
siRNAs and related non-silencing controls were synthesized by Qiagen-Xeragon 
(Germantown, MD, USA). For transfection, the Amaxa nucleofection technology (Amaxa; 
Koln, Germany) was employed [18]. JNK1/2 protein levels were analyzed by Western blot 
analysis 96 h after transfection. 
JNK activity in HSC lysates was detected using recombinant activating transcription factor-
2 (rATF2) as substrate [19]. 
Detection of intracellular and in vivo levels of ROS 
Intracellular levels of ROS were detected by means of the semi quantitative 2′,7′-
dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence technique, as previously 
detailed [20], in cells exposed to the desired stimulus for 15 min or to 50 μM hydrogen 
peroxide (H2O2, positive control). 
In vivo levels of ROS or 4-hydroxynonenal (HNE) were detected [16] and [21] on extracts 
obtained from the liver of control rats as well as of rats treated with a single dose of 
CCl4and then sacrificed 24, 48 and 72 h after treatment. 
Morphological analysis 
Indirect immunofluorescence was performed on liver cryostat sections from human 
biopsies from HCV cirrhotic patients (6 μm thick), as described [9]. Final dilution of primary 
antibodies was 1:250 (α-SMA), 1:50 (p-JNK1/2). Immune-positivity was revealed by the 
appropriate secondary Cy3-conjugated (1:1000 dilution) or Cy2-conjugated (1:200 dilution) 
antibodies (Amersham Pharmacia Biotech, Milano, Italy). Nuclei were stained using 4,6-
diamino-2-phenyilindole (DAPI) and slides were examined with an Olympus Fluoview 300 
confocal laser scanning microscope. 
Immunohistochemistry was performed on paraffin liver sections from patients with hepatitis 
C virus (HCV) related liver cirrhosis (METAVIR F4). The use of this material conforms to 
the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the 
University of Florence Human Research Review Committee. Sections (2 μm thick) were 
incubated with specific antibodies raised against phosphorylated JNK isoforms or α-SMA 
(final dilutions 1:30 and 1:1000, respectively). Briefly, after microwave antigen retrieval, 
primary antibodies were labelled by using EnVision, HRP-labelled System (DAKO) 
antibodies directed against rabbit antigen and visualized by 3′-diaminobenzidine substrate. 
Negative controls were performed by replacing the respective primary antibodies by 
isotype and concentrations matched irrelevant antibody. 
Statistical analysis 
Data in bar graphs represent means ± SEM, and were obtained from average data of at 
least three independent experiments. Luminograms and morphological images are 
representative of at least three experiments with similar results. Statistical analysis was 
performed by Student’s t-test or ANOVA for analysis of variance when appropriate 
(p <0.05 was considered significant). 
Results 
Migration of human HSC/MFs and MSCs in response to chemoattractants 
HSC/MFs (Fig. 1A), migrated significantly in response to PDGF-BB, MCP-1, VEGF, and 
superoxide anion, whereas hepatocyte growth factor (HGF), basic fibroblast growth factor 
(bFGF), and stromal cell-derived factor 1 (SDF-1 or CXCL12) were ineffective. Human 
MSCs (Fig. 1B) in their fibroblast-like phenotype migrated in response to a wider panel of 
stimuli including PDGF-BB, VEGF, MCP-1, X/XO, HGF, βFGF, and SDF-1. Angiotensin II 
(AT-II) was the only one able to elicit chemotaxis on both cell types. 
 Fig. 1.  
Migration of hHSC/MFs and hMSCs in response to 
chemoattractants. Wound healing assay (i) and chemotaxis assay (ii) were 
performed on hHSC/MFs (A) and hMSCs (B). Cells were either not treated 
(control) or treated with PDGF-BB (10 ng/ml), VEGF (100 ng/ml), MCP-1 
(100 ng/ml), HGF (20 ng/ml), βFGF (20 ng/ml), SDF1 (20 ng/ml), Ang II (nM) or 
XXO system (0.4 mM/2 mU). Data in bar graphs represent mean ± SEM (n = 4, 
in triplicate) and are expressed as number of cells migrated in the artificial lesion 
or in the filter of Boyden’s chambers. ∗p <0.05 and ∗∗p <0.01 versus control 
values. 
 
All pro-migratory polypeptides induced an early (15 min) activation of ERK1/2 and JNK1/2 
in HSC/MFs and MSCs, with increased phosphorylation of JNK1/2 being mostly limited to 
46 kDa isoforms (Fig. 2 A and B). 
 Fig. 2.  
Polypeptide factors induce migration through early activation of ERK1/2 and 
JNK1/2. Confluent and 24-h-starved HSC/MFs (A) and hMSCs (B) were incubated for 
15 min in the presence of chemoattractants. Levels of phosphorylated and 
unphosphorylated ERK1/2 (p44 and p42) (i) and JNK1/2 (p46 and p54) (ii) were detected 
in western blot analysis on total lysates by using specific antibodies. 
 
A PDGF-BB- (used as reference chemoattractant) and time-dependent analysis of ERK1/2 
and JNK1/2 phosphorylation revealed (Supplementary Fig. 1 A and B) that: (a) increased 
phosphorylation of ERK1/2 was detectable from 15 min until 4–6 h; (b) increased 
phosphorylation of 46 kDa JNK1/2 isoforms followed a biphasic pattern with an early 
activation detected at 15–30 min and a second peak at 2 h of incubation for HSC/MFs or 
afterwards for MSCs. 
Based on preliminary results, PDGF-BB, MCP-1, and VEGF were used throughout the 
study as positive stimuli to investigate in detail the involvement of ERK1/2 and JNK1/2. 
Pre-treatment with PD98095, pharmacological inhibitor of ERK1/2 upstream kinase MEK-
1, inhibited chemokinesis and chemotaxis in HSC/MFs, as previously 
reported, [6],[7], [8], [9], [10] and [11] and MSCs; similar results were obtained by pre-
treating cells with the pharmacological inhibitor of JNK1/2 SP600125 (Supplementary Fig. 
2A and B). In preliminary experiments we then selected an siRNA that significantly down-
regulated 46 kDa JNK1/2 isoforms in both cell types, and resulted in a significant decrease 
in JNK1/2 phosphorylation in response to PDGF-BB, chosen as a reference 
chemoattractant (Fig. 3A and B). When HSC/MFs and MSCs silenced for JNK1/2 were 
then exposed to PDGF-BB, VEGF, and MCP-1, chemotaxis was either significantly 
reduced (as for PDGF-BB) or almost abolished (Fig. 3A and B) as compared with cells 
carrying non-silencing siRNA (NsC). Moreover, as an additional proof of principle, 
experiments performed in mouse embryo fibroblasts from JNK1/2 double knock-out mice 
(MEF cells, Supplementary Fig. 3B) versus wild type fibroblasts revealed that only few 
MEF cells (15–20% in a typical experiment) migrated in response to PDGF-BB. To further 
explore the role of different isoforms we next employed siRNAs designed to silence JNK1 
or JNK2 isoforms in both cell types and in these conditions we found that, running both 
WHA and chemotaxis assays in response to PDGF-BB, the contribution of JNK1 isoforms 
to migration was more significant (Fig. 3C and D). 
 Fig. 3.  
JNK1/2 silencing inhibited polypeptide-dependent chemotaxis. hHSC/MFs 
(A and C) or hMSCs (B and D) were silenced for JNK1/2 (A and B) or for the 
single JNK1 or JNK2 isoforms (C and D). Total cell lysates (i) from JNK1/2 
silenced hHSC/MFs (A) or hMSCs (B), or cells transfected with a non-silencing 
control siRNA (NsC) were used in western blot analysis to evaluate 
phosphorylated and unphosphorylated JNK1/2 levels 96 h after transfection in 
cells treated or not with PDGF-BB, used as positive control. Chemotaxis (A–D) 
and chemokinesis (C and D) were always assessed in cells not transfected, cells 
transfected with NsC, and cells transfected with the desired siRNA. Cells were 
then either not treated (control cells) or treated with the indicated polypeptides 
(same concentrations as in Fig. 1 legend). Data are expressed as number of 
cells migrated in the artificial lesion or in the filter of Boyden’s chambers. Data in 
bar graphs represent mean ± SEM (n = 3, in triplicate) and are expressed as 
number of cells migrated in the artificial lesion or in the filter of Boyden’s 
chambers. ∗p <0.05 and ∗∗p <0.01 versus control values.#p <0.01 and ##p <0.05 
versus values in cells stimulated with polypeptide factors. 
Migration induced by polypeptide growth factors critically requires intracellular generation 
of ROS 
We next performed experiments to investigate whether intracellular generation of ROS 
may be critical in our experimental conditions. Preliminary experiments (Supplementary 
Fig. 4) performed with the pharmacological inhibitor of NADPH-oxidase 
diphenylphenylene-iodonium (DPI) indicated that: (a) DPI significantly inhibited or 
abolished chemokinesis and chemotaxis stimulated by PDGF-BB, MCP-1, and VEGF in 
HSC/MFs and MSCs; (b) DPI reduced phosphorylation of both ERK1/2 and JNK 46 kDa 
isoforms induced by PDGF-BB, was used as positive control. By employing the DCFH-DA 
semi-quantitative morphological technique, PDGF-BB, VEGF, and MCP-1 all induced an 
early (within 15 min) and significant increase in ROS-related intracellular fluorescence 
(Fig. 4A and B), a finding significantly prevented by pre-treating cells with the more specific 
NADPH-oxidase pharmacological inhibitor apocynin (Fig. 4C and D). Accordingly, 
apocynin also significantly inhibited polypeptide-induced chemokinesis and chemotaxis in 
HSC/MFs (Fig. 5A) and in MSCs (Fig. 5B). DPI and apocynin, at the experimental dose 
used, were completely ineffective on parameters of either necrotic or apoptotic cell death 
(Supplementary Fig. 4C and D). 
 
 Fig. 4.  
Intracellular generation of ROS in cells exposed to chemoattractants. 
Generation of intracellular ROS (green fluorescence) was detected by the semi-
quantitative technique based on the use of DCFH-DA at 15 min in control cells, 
HSC/MFs (A) and MSCs (B) treated with PDGF-BB (10 ng/ml), VEGF 
(100 ng/ml), MCP-1 (100 ng/ml), Menadione (0.1 μM), DMNQ (0.1 μM) or H2O2 
(50 μM), the latter used as positive control. When required, cells were pre-
treated for 1 h with apocynin 100 μM (C and D). For any condition, three images 
are offered of the same field representing phase contrast image (left column), 
DCFH-DA positive fluorescence (middle column), and their digital overlay (right 
column). 
 Fig. 5.  
Polypeptide-dependent migration required intracellular ROS 
production. Wound healing assay (i) and chemotaxis assay (ii) were performed 
on (A) hHSC/MFs and (B) hMSCs cells not exposed (control cells) or treated 
with VEGF (100 ng/ml), MCP-1 (100 ng/ml) or PDGF-BB (10 ng/ml) and, when 
required, pre-treated for 1 h with apocynin (100 μM). Data in bar graphs 
represent mean ± SEM (n = 4, in triplicate) and are expressed as number of 
cells migrated in the artificial lesion or in the filter of Boyden’s chambers.∗p <0.05 
and ∗∗p <0.01 versus control values. #p <0.01 and ##p <0.05 versus values in cells 
stimulated with polypeptide factors. 
Polypeptide-independent intracellular generation of ROS is sufficient to induce ERK1/2 
and JNK1/2 activation and migration 
In order to characterize the role of ROS in triggering migration, we employed 2-methyl-1,4-
naphthoquinone (Menadione, MEN) and 2,3-dimethoxy-1,4-naphthoquinone (DMNQ), 
which are known to induce in target cells a significant intracellular generation of 
superoxide and H2O2, respectively. In preliminary experiments, we found that 10 μM 
concentrations of MEN and DMNQ induced in HSC/MFs evident morphological changes or 
changes in LDH release or caspase 3 activation (Supplementary Fig. 5A–C). Since 
homologous results were found for MSCs (data not shown) MEN and DMNQ were 
employed in all experiments at 0.1 μM, a non-toxic dose resulting in intracellular 
generation of ROS in both cell types (Fig. 4A and B). 
Exposure of HSC/MFs and MSCs to MEN or DMNQ triggered an early and significant 
increased phosphorylation of ERK1/2 and JNK1/2 (Fig. 6A and B) as well as chemokinesis 
and chemotaxis that were again prevented by PD98095 (Supplementary Fig. 6A and B). 
Moreover, in cells silenced for JNK1/2 chemotaxis stimulated by MEN and DMNQ was 
significantly decreased (Fig. 6C and D), as compared to cells transfected with a non-
silencing RNA (NsC). 
 
 
 
Fig. 6.  
ROS-dependent migration was associated with activation of ERK1/2 and 
JNK1/2. Confluent and 24-h-starved (A) HSC/MFs and (B) MSCs were exposed to PDGF-
BB (10 ng/ml), Menadione (0.1 μM), DMNQ (0.1 μM), and XXO system (0.4 mM/2 mU). 
Total cell lysates were used in Western blotting to detect phosphorylated and 
unphosphorylated ERK1/2 (p44 and p42) (i) and JNK1/2 (p46 and p54) (ii) isoforms. 
Chemotaxis was assessed on (C) HSC/MFs or (D) MSCs that were either untransfected, 
transfected with NsC or with JNK1/2 siRNA and finally not treated (control cells) or treated 
with Menadione or DMNQ. Data in bar graphs represent mean ± SEM (n = 4, in triplicate) 
and are expressed as number of cells migrated in the filter of Boyden’s chambers. ∗p <0.05 
versus control values. #p <0.01 versus values in cells stimulated with Menadione and 
DMNQ. 
 
Increased generation of ROS and JNK activity in vivo 
In order to evaluate whether intracellular generation of ROS and JNK activation were likely 
to occur in vivo, activation of JNK1/2 was first investigated in cell extracts obtained from 
freshly isolated rat HSC obtained at different time points after administration of a single 
dose of CCl4, a model of acute liver injury in which oxidative stress is up-regulated from 
early time points (2–6 h) to 48–72 h [17] and [19], as shown by hepatic levels of ROS and 
4-hydroxynonenal (Fig. 7A and B). HSC lysates from CCl4-injured livers, in which 
activation of ERK1/2 was already reported [22], were characterized by a very significant 
increase of JNK activity (24 h) and (6 h) heme oxygenase 1 (HO-1), a cytoprotective 
enzyme that is considered a marker of ongoing oxidative stress (Fig. 7 C and D). HO-1 
protein levels were still elevated until 48 h and declined significantly starting from 72 h 
(data not shown). 
 
 
 
 Fig. 7.  
Oxidative stress“in vivo” was concomitant to JNK1/2 activation in HSC/MFs. In 
vivo oxidative stress was evaluated in terms of hepatic levels of (A) HNE or (B) ROS in 
liver samples obtained from rats receiving either CCl4 (1.25 ml/kg b.w.) or the vehicle 
alone (Control) and then sacrificed after 24, 48 and 72 h. Data in bar graphs, expressed as 
micromolar concentration in liver tissue (HNE) or as arbitrary units of fluorescence for mg 
of proteins (ROS), represent mean ± SEM and are referred to six animals for any 
experimental time point. ∗p <0.05 and ∗∗p <0.01 versus control values. (C) Total cell lysates 
were prepared from freshly isolated HSC obtained from rats treated with CCl4 or vehicle 
alone at the indicated time point. JNK assay was performed after JNK immunoprecipitation 
using recombinant activating transcription factor 2 (rATF2) as a substrate (upper panel). 
An aliquot of the immunobeads was analyzed for JNK levels by Western blotting (lower 
panel). (D) Lysates were prepared as described for panel (C) and levels of HO-1 were 
analyzed by Western blotting (upper panel). Membranes were reblotted for β-actin to 
assess equal loading (lower panel). 
 
As a second approach, immune-positivity for phosphorylated JNK isoforms (pJNKs) and α-
SMA was investigated on liver specimens from chronic HCV cirrhotic patients. 
Immunohistochemistry showed evident p-JNK positive nuclear staining for cells included in 
α-SMA positive fibrotic septa whereas hepatocytes exhibited only faint cytoplasmic 
positivity ( Fig. 8). Confocal laser microscopy analysis (indirect immunofluorescence on 
frozen specimens, Fig. 9) confirmed this scenario and was critical in showing unequivocal 
colocalization of p-JNK positive staining in several α-SMA-positive MFs within septa or at 
the interface between septa and parenchyma. 
 
 Fig. 8.  
Phosphorylated JNK isoforms and α-SMA in human cirrhosis. Immunohistochemistry 
was performed on paraffin serial sections from patients with hepatitis C virus (HCV) related 
liver cirrhosis (Metavir F4) using antibodies against α-SMA or phosphorylated-JNK. Upper 
panels (C): negative control. Original magnification as indicated. 
 
 Fig. 9.  
JNK1/2 activation in α-SMA positive cells in cirrhotic livers. Confocal laser microscopy 
was performed on liver cryostat sections from cirrhotic HCV patients. The panel includes: 
(A) tiny images on the left side representing image acquisition of single fluorescence 
identifying nuclei (1, blue fluorescence, DAPI staining), phosphorylated JNK isoforms (2, 
red fluorescence) and α-SMA (3, green fluorescence); (B) a larger image (overlay) offering 
electronic merging of fluorescent images. White arrows indicate colocalization between α-
SMA and phosphorylated JNKs. 
Discussion 
Migration in response to chemoattractant polypeptides or other mediators generated 
during CLDs represents a distinctive feature of HSC/MFs and hepatic MFs of different 
origin [1], [2], [3], [4] and [5], leading these cells to align with inflammatory cells along 
fibrotic septa during fibrogenic progression. The present study provides the following major 
original messages: (a) intracellular generation of ROS and related activation of JNK1/2 
isoforms (as for ERK1/2) are critical steps in the induction of chemotaxis in both human 
HSC/MFs and fibroblastic-like, α-SMA-positive human bone marrow-derived MSCs; (b) in 
both cell types, these common signaling mechanisms are triggered by polypeptide 
chemoattractants, but polypeptide-independent intracellular generation of ROS is sufficient 
to trigger chemotaxis; (c) human HSC/MFs and fibroblastic-like MSCs respond to a 
common panel of pro-fibrogenic and pro-migratory signals generated in CLDs. 
Migration of human HSC/MFs in response to chemoattractants was already reported to 
involve the Ras/ERK pathway [1], [3], [7], [8] and [9], with only PDGF [1], [3] and [7] being 
able to activate the PI-3 K/c-Akt pathway. The involvement of a more complex scenario 
was first suggested by studies showing that either skin fibroblasts [23] or rat 
HSC [24]migrated in response to PDGF-BB by a pathway involving transient activation of 
JNK isoforms, a scenario that our study revealed to be common to all effective polypeptide 
chemoattractants. 
Since the involvement of the Ras/ERK pathway was already characterized in the literature, 
we then focused on the role of intracellular generation of ROS and of transient activation of 
JNK1/2. JNKs are redox sensitive serine/threonine protein kinases involved in a number of 
“stressful” conditions, including inflammation, differentiation, apoptosis, and insulin 
resistance [25] and [26] as well as in the growth factor – dependent regulation of migration 
and epithelial morphogenesis [27]. A mechanistic relationship between polypeptide-
dependent JNK1/2 activation and migration was unequivocally shown by silencing an 
evolutionary conserved sequence common to both JNK1 and JNK2 isoforms or in 
fibroblasts obtained from mouse embryos with targeted deletion of both JNK isoforms. 
Since polypeptide-dependent activation of JNK1/2 was an early (within 15 min), transient 
(i.e., unable to induce apoptosis) and specific event, being mostly limited to 46 kDa 
isoforms, silencing of both JNK1 and JNK2 was the starting reasonable experimental 
choice because: (a) alternative splicing of JNK1 and JNK2 leads to eight different isoforms 
of 54 and 46 kDa, the latter molecular weight including JNK1α1, JNK1β1, JNK2α1, and 
JNK2β1 isoforms [25]; (b) the combined deficiency for both isoforms in double knock out 
mice is lethal in embryo development. However, it should be noted that under conditions of 
specific selective silencing, we observed that JNK1 silencing was more effective in 
inhibiting migration and chemotaxis, suggesting a prevalent role for JNK1 according to 
recent published data [28] and [29]. 
In our study, a critical pro-migratory role for ROS-mediated JNK activation was outlined by 
the following in vitro findings: (1) exposure of human HSC/MFs and MSCs to PDGF-BB, 
VEGF, MCP-1, MEN or DMNQ resulted in an early increase in intracellular ROS 
generation; (2) JNK1/2 activation and migration were reproduced simply by exposing cells 
to non-cytotoxic levels of either MEN or DMNQ, two redox-cycling chemicals able to 
generate intracellular superoxide anion or hydrogen peroxide, respectively; (3) 
polypeptide-dependent activation of JNK1/2 (and ERK1/2) by ROS and subsequent 
migration were prevented by inhibiting NADPH-oxidase, a ROS-generating membrane that 
may contribute to most of the polypeptide-induced phenotypical response of 
HSC/MFs [30]; (4) ROS-dependent migration was almost abolished in HSC/MFs and 
MSCs silenced for JNK1/2. 
Human and experimental in vivo data further support this scenario: (1) in HCV cirrhotic 
human livers, positivity for phosphorylated JNK1/2 isoforms was mainly detected in α-SMA 
positive MFs located within fibrotic septa or at the interface between septa and 
parenchyma, a scenario consistent with the one reported by Kluwe et al. [29]; (2) activation 
of JNK1/2, preceded by up-regulation of HO-1 expression, a typical redox-sensitive 
gene [31], was detected at an early time point (i.e., within 24 h) in cell extracts obtained 
from rat HSC/MFs isolated by acutely injured livers suggesting that “in vivo” HSC/MFs 
were indeed exposed to oxidative stress. 
In conclusion, migration/chemotaxis of human HSC/MFs and MSCs stimulated by 
polypeptides critically requires NADPH-oxidase dependent increased generation of 
intracellular ROS and the consequent activation of JNK1/2 isoforms in addition to 
activation of Ras/ERK signaling. Moreover, ROS released in the context of chronic liver 
injury by damaged hepatocytes or activated inflammatory cells may induce 
migration/chemotaxis in both cell types that have been shown to contribute to liver 
fibrogenesis [1], [2], [3] and [4]. The overall scenario emerging from the present study, 
which is fully in agreement with the recent hypothesis of JNK being involved in HSC 
activation and fibrogenesis [29], further suggests JNK as a common putative therapeutic 
target for antioxidants and/or small molecules such as protein kinase inhibitors. 
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